Quizzes

Quiz

Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer

06/13/2024

True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.

True or False: Five-year...

06/13/2024

Oncology

Quiz

Lisocabtagene Maraleucel Approved for Patients With R/R FL

06/05/2024

True or False: The FDA’s accelerated approval of lisocabtagene maraleucel for patients with R/R follicular lymphoma was based on results from a primary efficacy population of 94 patients with PET-positive disease at baseline or following...

True or False: The FDA’s...

06/05/2024

Oncology

Quiz

Safety of Oral Decitabine Cedazuridine vs Intravenous Decitabine for Patients With MDS or CML

06/02/2024

Oncology

Quiz

Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma

05/30/2024

Oncology

Quiz

FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

05/29/2024

According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?

According to results from the...

05/29/2024

Oncology

Quiz

Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL

04/11/2024

Oncology

Quiz

Post-Progression Median PFS With Monotherapy for Endometrial Cancer

04/10/2024

What was the median progression-free survival for endometrial cancer treated with monotherapy after disease progression following initial treatment?

What was the median...

04/10/2024

Oncology

Quiz

Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

04/04/2024

According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?

According to results from the...

04/04/2024

Oncology

Quiz

Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

04/04/2024

True or False: Results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial demonstrated that tisotumab vedotin in the second-/third-line setting significantly improved survival and response outcomes compared to chemotherapy for patients with...

True or False: Results from the...

04/04/2024

Oncology

Quiz

Efficacy of Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Following ASCT

04/02/2024

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology